Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation

Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation

Unlike most other primary epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC), exon 20 insertions, comprising approximately 4% to 10% of all EGFR mutations, are generally considered to be resistant to EGFR tyrosine kinase inhibitors (TKIs). However, EGFR exon 20 i...

Full description

Bibliographic Details
Main Authors: Sabine Zöchbauer-Müller, Bettina Kaserer, Helmut Prosch, Agnieszka Cseh, Flavio Solca, Markus Johann Bauer, Leonhard Müllauer
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-01-01
Series:Frontiers in Oncology
Subjects:
afatinib
EGFR mutation
exon 20 insertion
H773dup
long-term response
NSCLC
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.593852/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.593852/full

Similar Items